Compound 17

Compound 17 is a non-specific designation used in medicinal chemistry to identify specific lead candidates within a synthesized series. In the provided context, it refers to two distinct experimental small molecules. The first, often specified as **Compound 17b**, is a biased agonist of **formyl peptide receptor 1 (FPR1)** and **formyl peptide receptor 2 (FPR2)** developed by researchers at **Monash University**. It acts as an annexin-A1 mimetic, demonstrating cardioprotective, anti-inflammatory, and anti-fibrotic properties in preclinical models of myocardial infarction and pulmonary hypertension. The second is a **2-phenylimidazo[1,2-a]-pyridine derivative** that acts as a positive allosteric modulator of the **alpha1beta2gamma2 GABA-A receptor**. This compound has shown potential as an antipsychotic and neuroprotective agent in schizophrenia models, reversing hyperlocomotion without sedative side effects. Both versions are currently research-stage compounds and have not been approved for clinical use.

Other names

2-phenylimidazo[1,2-a]-pyridine derivativeFPR1/FPR2 biased agonist